A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver.

Trial Profile

A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2013

At a glance

  • Drugs Melphalan (Primary)
  • Indications Cancer metastases; Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 07 Aug 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 25 Sep 2011 Additional results from the metastatic neuroendocrine tumour cohort (n=24) presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress, as reported in a Delcath Systems media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top